INTEGRA LIFESCIENCES HOLDINGS CORP Operating Lease, Right-of-Use Asset, Amortization Expense
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $3.04 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-10-26.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2022-10-26
- INTEGRA LIFESCIENCES HOLDINGS CORP operating lease, right-of-use asset, amortization expense for the quarter ending 2022-09-30 was $1.65M, a 188.44% increase year-over-year.
- INTEGRA LIFESCIENCES HOLDINGS CORP operating lease, right-of-use asset, amortization expense for the quarter ending 2022-06-30 was $1.41M, a 40.16% increase year-over-year.
- INTEGRA LIFESCIENCES HOLDINGS CORP operating lease, right-of-use asset, amortization expense for the quarter ending 2022-03-31 was -$17.00K, a 101.12% decline year-over-year.
- INTEGRA LIFESCIENCES HOLDINGS CORP operating lease, right-of-use asset, amortization expense for the quarter ending 2021-09-30 was $571.00K, a 38.59% increase year-over-year.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month |
|---|---|---|---|
| 2022-09-30 | $1.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-26 | $3.06M derived: sum of 2 quarters · filed 2022-10-26 | $3.04M 10-Q · filed 2022-10-26 |
| 2022-06-30 | $1.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | $1.39M 10-Q · filed 2022-07-27 | |
| 2022-03-31 | -$17.00K 10-Q · filed 2022-04-27 | ||
| 2021-09-30 | $571.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-26 | $1.58M derived: sum of 2 quarters · filed 2022-10-26 | $3.10M 10-Q · filed 2022-10-26 |
| 2021-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | $2.53M 10-Q · filed 2022-07-27 | |
| 2021-03-31 | $1.52M 10-Q · filed 2022-04-27 | ||
| 2020-09-30 | $412.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $1.99M derived: sum of 2 quarters · filed 2021-11-02 | $2.17M 10-Q · filed 2021-11-02 |
| 2020-06-30 | $1.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $1.76M 10-Q · filed 2021-07-29 | |
| 2020-03-31 | $178.00K 10-Q · filed 2021-04-29 | ||
| 2019-09-30 | $3.47M 10-Q · filed 2020-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |